Literature DB >> 16200577

Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?

Josef S Smolen1, Daniel Aletaha, Edward Keystone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16200577     DOI： 10.1002/art.21293

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  22 in total

1.  [Early and advanced rheumatoid arthritis. Diagnosis and state of the art therapy strategy].

Authors:  J Wollenhaupt; K Krüger
Journal:  Z Rheumatol       Date:  2012-01       Impact factor: 1.372

Review 2.  [Activity-score based therapy in rheumatoid arthritis].

Authors:  K Machold; V Nell; D Aletaha; J Smolen; T Stamm
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

3.  Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.

Authors:  Hilary A Capell; Rajan Madhok; Duncan R Porter; Robin A L Munro; Iain B McInnes; John A Hunter; Malcolm Steven; Asad Zoma; Elaine Morrison; Martin Sambrook; Fat Wui Poon; Rosemary Hampson; Fiona McDonald; Ann Tierney; Neil Henderson; Ian Ford
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

Review 4.  Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials.

Authors:  Amy C Cannella; James R O'Dell
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.

Authors:  B Combe; C Codreanu; U Fiocco; M Gaubitz; P P Geusens; T K Kvien; K Pavelka; P N Sambrook; J S Smolen; J Wajdula; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

6.  Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.

Authors:  M Schoels; T Kapral; T Stamm; J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2007-02-16       Impact factor: 19.103

Review 7.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maxime Dougados; Paul Emery; Cecile Gaujoux-Viala; Simone Gorter; Rachel Knevel; Jackie Nam; Monika Schoels; Daniel Aletaha; Maya Buch; Laure Gossec; Tom Huizinga; Johannes W J W Bijlsma; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Cem Gabay; Juan Gomez-Reino; Marios Kouloumas; Tore K Kvien; Emilio Martin-Mola; Iain McInnes; Karel Pavelka; Piet van Riel; Marieke Scholte; David L Scott; Tuulikki Sokka; Guido Valesini; Ronald van Vollenhoven; Kevin L Winthrop; John Wong; Angela Zink; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

Review 8.  Limits of add-on trials: antirheumatic drugs.

Authors:  Laura Ottolenghi; Vittorio Bertele'; Silvio Garattini
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

Review 9.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

10.  Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway.

Authors:  I González-Alvaro; A M Ortiz; C Domínguez-Jiménez; A Aragón-Bodi; B Díaz Sánchez; F Sánchez-Madrid
Journal:  Ann Rheum Dis       Date:  2008-10-28       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.